BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015;13:2140-2151. [PMID: 26284591 DOI: 10.1016/j.cgh.2015.08.014] [Cited by in Crossref: 269] [Cited by in F6Publishing: 276] [Article Influence: 38.4] [Reference Citation Analysis]
Number Citing Articles
1 Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017;551:340-345. [PMID: 29144460 DOI: 10.1038/nature24302] [Cited by in Crossref: 174] [Cited by in F6Publishing: 173] [Article Influence: 34.8] [Reference Citation Analysis]
2 Fujiwara N, Liu P, Athuluri-divakar SK, Zhu S, Hoshida Y. Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 3-25. [DOI: 10.1007/978-3-030-21540-8_1] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Balasus D, Way M, Fusilli C, Mazza T, Morgan MY, Cervello M, Giannitrapani L, Soresi M, Agliastro R, Vinciguerra M, Montalto G. The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population. Oncotarget 2016;7:86791-802. [PMID: 27888630 DOI: 10.18632/oncotarget.13558] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
4 Liu XN, Cui DN, Li YF, Liu YH, Liu G, Liu L. Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol 2019; 25(30): 4199-4212 [PMID: 31435173 DOI: 10.3748/wjg.v25.i30.4199] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
5 Huang X, Lee F, Teng Y, Lingam CB, Chen Z, Sun M, Song Z, Balachander GM, Leo HL, Guo Q, Shah I, Yu H. Sequential drug delivery for liver diseases. Adv Drug Deliv Rev 2019;149-150:72-84. [PMID: 31734169 DOI: 10.1016/j.addr.2019.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Benbow JH, Elam AD, Bossi KL, Massengill DL, Brandon-Warner E, Anderson WE, Culberson CR, Russo MW, deLemos AS, Schrum LW. Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study. Dig Dis Sci 2018;63:653-64. [PMID: 29330728 DOI: 10.1007/s10620-017-4860-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sun C, Li G, Liu M. A Novel Circular RNA, circ_0005394, Predicts Unfavorable Prognosis and Contributes to Hepatocellular Carcinoma Progression by Regulating miR-507/E2F3 and miR-515-5p/CXCL6 Signaling Pathways. Onco Targets Ther 2020;13:6171-80. [PMID: 32636641 DOI: 10.2147/OTT.S256238] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Debes JD, Boonstra A, de Knegt RJ. NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse. Hepatology 2020;71:774-6. [PMID: 32039490 DOI: 10.1002/hep.31170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Kasmari AJ, Welch A, Liu G, Leslie D, McGarrity T, Riley T. Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. Am J Med. 2017;130:746.e1-746.e7. [PMID: 28109969 DOI: 10.1016/j.amjmed.2016.12.029] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 10.4] [Reference Citation Analysis]
11 Johnson PJ, Berhane S, Walker AJ, Gordon FH, Ryder SD, McPherson S, Sreedharan A, Ustianowski AA, Agarwal K, Mutimer D, Kumada T, Toyoda H, Irving WL; HCV Research UK. Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. J Viral Hepat 2021;28:168-76. [PMID: 32978982 DOI: 10.1111/jvh.13408] [Reference Citation Analysis]
12 Sakisaka M, Haruta M, Komohara Y, Umemoto S, Matsumura K, Ikeda T, Takeya M, Inomata Y, Nishimura Y, Senju S. Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-β. J Hepatobiliary Pancreat Sci 2017;24:109-19. [PMID: 28008721 DOI: 10.1002/jhbp.422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
13 Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, Giannini EG, Granito A, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cammà C, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver Int 2017;37:259-70. [PMID: 27427866 DOI: 10.1111/liv.13204] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
14 Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122-132. [PMID: 27924080 DOI: 10.1038/nrgastro.2016.176] [Cited by in Crossref: 196] [Cited by in F6Publishing: 191] [Article Influence: 32.7] [Reference Citation Analysis]
15 Wegermann K, Hyun J, Diehl AM. Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer. Clin Liver Dis (Hoboken) 2021;17:6-10. [PMID: 33552478 DOI: 10.1002/cld.1006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Feng T, Dzieran J, Yuan X, Dropmann A, Maass T, Teufel A, Marhenke S, Gaiser T, Rückert F, Kleiter I, Kanzler S, Ebert MP, Vogel A, Ten Dijke P, Dooley S, Meindl-Beinker NM. Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice. Oncogenesis 2017;6:e294. [PMID: 28134936 DOI: 10.1038/oncsis.2016.85] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
17 Weber A, Heikenwalder M. P(URI)fying Novel Drivers of NASH and HCC: A Feedforward Loop of IL17A via White Adipose Tissue. Cancer Cell 2016;30:15-7. [PMID: 27411585 DOI: 10.1016/j.ccell.2016.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Bello HR, Mahdi ZK, Lui SK, Nandwana SB, Harri PA, Davarpanah AH. Hepatocellular Carcinoma With Atypical Imaging Features: Review of the Morphologic Hepatocellular Carcinoma Subtypes With Radiology-Pathology Correlation. J Magn Reson Imaging 2021. [PMID: 33682266 DOI: 10.1002/jmri.27553] [Reference Citation Analysis]
19 Chen J, Zaidi S, Rao S, Chen JS, Phan L, Farci P, Su X, Shetty K, White J, Zamboni F, Wu X, Rashid A, Pattabiraman N, Mazumder R, Horvath A, Wu RC, Li S, Xiao C, Deng CX, Wheeler DA, Mishra B, Akbani R, Mishra L. Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway. Gastroenterology 2018;154:195-210. [PMID: 28918914 DOI: 10.1053/j.gastro.2017.09.007] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
20 Lu X, Ding Y, Liu H, Sun M, Chen C, Yang Y, Wang H. The Role of Hydrogen Sulfide Regulation of Autophagy in Liver Disorders. Int J Mol Sci 2022;23:4035. [PMID: 35409395 DOI: 10.3390/ijms23074035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Shao J, Meng Q, Li Y. Theaflavins suppress tumor growth and metastasis via the blockage of the STAT3 pathway in hepatocellular carcinoma. Onco Targets Ther 2016;9:4265-75. [PMID: 27478384 DOI: 10.2147/OTT.S102858] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
22 Wu Y, Li X, Chen M, Liu Z, Zhang X, Zheng S, Xu X. Phosphorylation of PED/PEA-15 at Ser116 and phosphorylation of p27 at Thr187 indicates a poor prognosis in hepatocellular carcinoma. Oncol Lett 2021;21:177. [PMID: 33574916 DOI: 10.3892/ol.2021.12438] [Reference Citation Analysis]
23 Yi B, Tang C, Tao Y, Zhao Z. Definition of a novel vascular invasion-associated multi-gene signature for predicting survival in patients with hepatocellular carcinoma. Oncol Lett 2020;19:147-58. [PMID: 31897125 DOI: 10.3892/ol.2019.11072] [Reference Citation Analysis]
24 Grgurevic I, Tjesic Drinkovic I, Pinzani M. Multiparametric ultrasound in liver diseases: an overview for the practising clinician. Postgrad Med J 2019;95:425-32. [PMID: 30665903 DOI: 10.1136/postgradmedj-2018-136111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Wu W, Yang JL, Wang YL, Wang H, Yao M, Wang L, Gu JJ, Cai Y, Shi Y, Yao DF. Reversal of multidrug resistance of hepatocellular carcinoma cells by metformin through inhibiting NF-κB gene transcription. World J Hepatol 2016; 8(23): 985-993 [PMID: 27621764 DOI: 10.4254/wjh.v8.i23.985] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
26 Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol. 2018;6:69-78. [PMID: 29607307 DOI: 10.14218/jcth.2017.00031] [Cited by in Crossref: 97] [Cited by in F6Publishing: 76] [Article Influence: 19.4] [Reference Citation Analysis]
27 Catania R, Chupetlovska K, Borhani AA, Maheshwari E, Furlan A. Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications. Abdom Radiol (NY) 2021;46:5723-34. [PMID: 34519877 DOI: 10.1007/s00261-021-03270-x] [Reference Citation Analysis]
28 Saitta C, Pollicino T, Raimondo G. Obesity and liver cancer. Ann Hepatol 2019;18:810-5. [PMID: 31543467 DOI: 10.1016/j.aohep.2019.07.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
29 Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: Present and future. Med Clin (Barc). 2018;150:390-397. [PMID: 29096967 DOI: 10.1016/j.medcli.2017.08.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
30 Sinn DH, Kang D, Kang M, Paik SW, Guallar E, Cho J, Gwak GY. Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. BMC Cancer 2019;19:286. [PMID: 30922251 DOI: 10.1186/s12885-019-5508-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. Medicine (Baltimore) 2016;95:e4832. [PMID: 27603400 DOI: 10.1097/MD.0000000000004832] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
32 Moslehi A, Hamidi-Zad Z. Role of SREBPs in Liver Diseases: A Mini-review. J Clin Transl Hepatol 2018;6:332-8. [PMID: 30271747 DOI: 10.14218/JCTH.2017.00061] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
33 Pandya P, Kanwal F. Adding to the evidence base: Effectiveness of hepatocellular carcinoma surveillance in clinical practice. Hepatol Commun 2017;1:723-5. [PMID: 29404488 DOI: 10.1002/hep4.1087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Sepehri Z, Kiani Z, Kohan F, Alavian SM, Ghavami S. Toll like receptor 4 and hepatocellular carcinoma; A systematic review. Life Sci 2017;179:80-7. [PMID: 28472619 DOI: 10.1016/j.lfs.2017.04.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
35 Zheng L, Deng CL, Wang L, Huang XB, You N, Tang YC, Wu K, Liang P, Mi N, Li J. COMMD7 is correlated with a novel NF-κB positive feedback loop in hepatocellular carcinoma. Oncotarget 2016;7:32774-84. [PMID: 27129158 DOI: 10.18632/oncotarget.9047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
36 Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Reference Citation Analysis]
37 Qin H, Wen DY, Que Q, Zhou CY, Wang XD, Peng YT, He Y, Yang H, Liao BM. Reduced expression of microRNA-139-5p in hepatocellular carcinoma results in a poor outcome: An exploration the roles of microRNA-139-5p in tumorigenesis, advancement and prognosis at the molecular biological level using an integrated meta-analysis and bioinformatic investigation. Oncol Lett 2019;18:6704-24. [PMID: 31807180 DOI: 10.3892/ol.2019.11031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Tran SA, Le A, Zhao C, Hoang J, Yasukawa LA, Weber S, Henry L, Nguyen MH. Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol 2018;5:e000192. [PMID: 29607053 DOI: 10.1136/bmjgast-2017-000192] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
39 Peng L, Ye R, Zhu X, Xie Y, Zhong B, Liu Y, Li H, Xie B, Ortega A. LINC02273 Promotes Hepatocellular Carcinoma Progression via Retaining β-Catenin in the Nucleus to Augment Wnt Signaling. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/9631036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Brito AF, Abrantes AM, Tralhão JG, Botelho MF. Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev 2016;10:302. [PMID: 27994769 DOI: 10.4081/oncol.2016.302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
41 Melaram R. Environmental Risk Factors Implicated in Liver Disease: A Mini-Review. Front Public Health 2021;9:683719. [PMID: 34249849 DOI: 10.3389/fpubh.2021.683719] [Reference Citation Analysis]
42 Li MX, Zhao H, Bi XY, Li ZY, Yao XS, Li H, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Zhao DB, Cai JQ. Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area. Oncotarget 2016;7:86630-47. [PMID: 27880930 DOI: 10.18632/oncotarget.13428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
43 El‐serag HB. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 758-72. [DOI: 10.1002/9781119436812.ch59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
44 Huo Q, Ge C, Tian H, Sun J, Cui M, Li H, Zhao F, Chen T, Xie H, Cui Y, Yao M, Li J. Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity. Cell Death Dis 2017;8:e2766. [PMID: 28471446 DOI: 10.1038/cddis.2017.165] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
45 White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017;152:812-820.e5. [PMID: 27889576 DOI: 10.1053/j.gastro.2016.11.020] [Cited by in Crossref: 222] [Cited by in F6Publishing: 204] [Article Influence: 37.0] [Reference Citation Analysis]
46 Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int 2021;41:915-27. [PMID: 33641230 DOI: 10.1111/liv.14843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MB. Access to Liver Transplantation for Hepatocellular Carcinoma: Does Candidate Age Matter? J Am Coll Surg 2021;233:140-51. [PMID: 33652155 DOI: 10.1016/j.jamcollsurg.2021.01.018] [Reference Citation Analysis]
48 Singal AG, Lok AS, Feng Z, Kanwal F, Parikh ND. Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31297-0. [PMID: 32961340 DOI: 10.1016/j.cgh.2020.09.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
49 Gui L, Zhu YW, Xu Q, Huang JJ, Hua P, Wu GJ, Lu J, Ni JB, Tang H, Zhang LL. RNA interference-mediated downregulation of phospholipid scramblase 1 expression in primary liver cancer in vitro. Oncol Lett 2020;20:361. [PMID: 33133261 DOI: 10.3892/ol.2020.12225] [Reference Citation Analysis]
50 Imai K, Takai K, Miwa T, Taguchi D, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers (Basel) 2019;11:E1206. [PMID: 31430945 DOI: 10.3390/cancers11081206] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
51 Faivre M, Cottet V, Bour JB, Richou C, Valmary-Degano S, Thiefin G, Andreoletti L, Geist C, Schvoerer E, Malvé B, Habersetzer F, Fafi-Kremer S, Binquet C, Jouve JL, Bronowicki JP, Doffoel M, Hillon P, Herbein G, Monnet E, Di Martino V; CirCE Study Group. Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis: A Preliminary Study. J Clin Gastroenterol 2019;53:236-41. [PMID: 30383568 DOI: 10.1097/MCG.0000000000001039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
52 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14:99-114. [DOI: 10.1038/nrendo.2017.173] [Cited by in Crossref: 142] [Cited by in F6Publishing: 122] [Article Influence: 28.4] [Reference Citation Analysis]
53 Liu RR, Lv YS, Tang YX, Wang YF, Chen XL, Zheng XX, Xie SZ, Cai Y, Yu J, Zhang XN. Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species. Oncotarget. 2016;7:24348-24360. [PMID: 27028999 DOI: 10.18632/oncotarget.8324] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
54 Wang M, Comunale MA, Herrera H, Betesh L, Kono Y, Mehta A. Identification of IgM as a contaminant in lectin-FLISA assays for HCC detection. Biochem Biophys Res Commun 2016;476:140-5. [PMID: 27181357 DOI: 10.1016/j.bbrc.2016.05.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
55 Zhang YL, Xue G, Miao H, Zhou CC, Sun SH, Zhang Y. Folic acid supplementation acts as a chemopreventive factor in tumorigenesis of hepatocellular carcinoma by inducing H3K9Me2-dependent transcriptional repression of LCN2. Oncotarget 2021;12:366-78. [PMID: 33659047 DOI: 10.18632/oncotarget.27136] [Reference Citation Analysis]
56 Jie M, Hai-xia L, Fei-fei T, Shu-ling L, Tian-yi F, Xue-qian W, Qing-guo W, Fa-feng C. Systematic Investigation of Berberine for Treating Hepatocellular Carcinoma Based on Network Pharmacology. Digital Chinese Medicine 2019;2:127-35. [DOI: 10.1016/j.dcmed.2019.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
57 Han J, Xie C, Pei T, Wang J, Lan Y, Huang K, Cui Y, Wang F, Zhang J, Pan S, Liang Y, Zhen T, Song R, Sun B, Li Y, Shi H, Yang G, Liu X, Zhu M, Wang Y, Li K, Liu Y, Meng F, Liao F, Meng X, Hong X, Liu L. Deregulated AJAP1/β-catenin/ZEB1 signaling promotes hepatocellular carcinoma carcinogenesis and metastasis. Cell Death Dis 2017;8:e2736. [PMID: 28383563 DOI: 10.1038/cddis.2017.126] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
58 Liang CW, Yang HC, Islam MM, Nguyen PAA, Feng YT, Hou ZY, Huang CW, Poly TN, Li YJ. Predicting Hepatocellular Carcinoma With Minimal Features From Electronic Health Records: Development of a Deep Learning Model. JMIR Cancer 2021;7:e19812. [PMID: 34709180 DOI: 10.2196/19812] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res. 2019;49:14-32. [PMID: 30308081 DOI: 10.1111/hepr.13259] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
60 Wu M, Sun T, Xing L. Circ_0004913 Inhibits Cell Growth, Metastasis, and Glycolysis by Absorbing miR-184 to Regulate HAMP in Hepatocellular Carcinoma. Cancer Biother Radiopharm 2020. [PMID: 33021399 DOI: 10.1089/cbr.2020.3779] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
61 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 367] [Article Influence: 91.3] [Reference Citation Analysis]
62 Li Z, Wu L, Tan W, Zhang K, Lin Q, Zhu J, Tu C, Lv X, Jiang C. MiR-20b-5p promotes hepatocellular carcinoma cell proliferation, migration and invasion by down-regulating CPEB3. Ann Hepatol 2021;23:100345. [PMID: 33812045 DOI: 10.1016/j.aohep.2021.100345] [Reference Citation Analysis]
63 El-serag HB, Kramer J, Duan Z, Kanwal F. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat 2016;23:687-96. [DOI: 10.1111/jvh.12533] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
64 Vande Lune P, Abdel Aal AK, Klimkowski S, Zarzour JG, Gunn AJ. Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. J Clin Transl Hepatol 2018;6:175-88. [PMID: 29951363 DOI: 10.14218/JCTH.2017.00045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
65 Gu JJ, Yao M, Yang J, Cai Y, Zheng WJ, Wang L, Yao DB, Yao DF. Mitochondrial carnitine palmitoyl transferase-II inactivity aggravates lipid accumulation in rat hepatocarcinogenesis. World J Gastroenterol 2017; 23(2): 256-264 [PMID: 28127199 DOI: 10.3748/wjg.v23.i2.256] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
66 Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, Wang B, Zhan S, Kong Y, Jia J, You H, Yang H. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.02.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
67 Liu J, Li W, Zhang J, Ma Z, Wu X, Tang L. Identification of key genes and long non-coding RNA associated ceRNA networks in hepatocellular carcinoma. PeerJ 2019;7:e8021. [PMID: 31695969 DOI: 10.7717/peerj.8021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
68 Garancini M, Pinotti E, Nespoli S, Romano F, Gianotti L, Giardini V. Hepatic resection beyond barcelona clinic liver cancer indication: When and how. World J Hepatol 2016; 8(11): 513-519 [PMID: 27099652 DOI: 10.4254/wjh.v8.i11.513] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
69 Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:238-51. [PMID: 31900465 DOI: 10.1038/s41575-019-0240-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
70 Rao CV, Asch AS, Yamada HY. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis. 2017;38:2-11. [PMID: 27838634 DOI: 10.1093/carcin/bgw118] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 9.3] [Reference Citation Analysis]
71 Mihor A, Tomsic S, Zagar T, Lokar K, Zadnik V. Socioeconomic inequalities in cancer incidence in Europe: a comprehensive review of population-based epidemiological studies. Radiol Oncol 2020;54:1-13. [PMID: 32074075 DOI: 10.2478/raon-2020-0008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
72 Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J, Shi X. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res 2018;37:324. [PMID: 30591064 DOI: 10.1186/s13046-018-0965-2] [Cited by in Crossref: 97] [Cited by in F6Publishing: 111] [Article Influence: 24.3] [Reference Citation Analysis]
73 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 196] [Article Influence: 39.6] [Reference Citation Analysis]
74 Borges KA, Dai J, Parikh ND, Schwartz M, Nguyen MH, Roberts LR, Befeler AS, Srivastava S, Rinaudo JA, Feng Z, Marrero JA, Reddy KR. Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network. Contemp Clin Trials 2019;76:49-54. [PMID: 30439517 DOI: 10.1016/j.cct.2018.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
75 Pan F, Lin X, Hao L, Wang T, Song H, Wang R. The Critical Role of Ferroptosis in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:882571. [DOI: 10.3389/fcell.2022.882571] [Reference Citation Analysis]
76 Pan F, Lin XR, Hao LP, Chu XY, Wan HJ, Wang R. The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives. Front Cell Dev Biol 2021;9:674919. [PMID: 34046411 DOI: 10.3389/fcell.2021.674919] [Reference Citation Analysis]
77 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in Southern Sweden: a population-based study. Scand J Gastroenterol 2019;54:1027-32. [PMID: 31389730 DOI: 10.1080/00365521.2019.1649454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
78 Mantovani A, Turino T, Lando MG, Gjini K, Byrne CD, Zusi C, Ravaioli F, Colecchia A, Maffeis C, Salvagno G, Lippi G, Bonora E, Targher G. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 2019;. [PMID: 31786361 DOI: 10.1016/j.diabet.2019.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
79 Brar G, Greten TF, Graubard BI, McNeel TS, Petrick JL, McGlynn KA, Altekruse SF. Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. Hepatol Commun 2020;4:1541-51. [PMID: 33024922 DOI: 10.1002/hep4.1564] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
80 Zhang C, Niu Y, Wang Z, Xu X, Li Y, Ma L, Wang J, Yu Y. Corosolic acid inhibits cancer progression by decreasing the level of CDK19-mediated O-GlcNAcylation in liver cancer cells. Cell Death Dis 2021;12:889. [PMID: 34588426 DOI: 10.1038/s41419-021-04164-y] [Reference Citation Analysis]
81 Ding Y, Sun Z, Zhang S, Zhou L, Xu Q, Zhou D, Li Y, Han X, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma. Dis Markers 2020;2020:8879944. [PMID: 33062075 DOI: 10.1155/2020/8879944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Karin M. New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. Precis Clin Med. 2018;1:21-28. [PMID: 30687560 DOI: 10.1093/pcmedi/pby005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
83 Wang S, Sun H, Xie Z, Li J, Hong G, Li D, Mallampati S, Zhou X, Zhou C, Zhang H, Cheng Z, Shan H, Ma H. Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983-2012. Oncotarget 2016;7:59820-33. [PMID: 27486977 DOI: 10.18632/oncotarget.10930] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
84 Amaro CP, Tam VC. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond. Curr Oncol 2020;27:S173-80. [PMID: 33343211 DOI: 10.3747/co.27.7103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Lou W, Chen J, Ding B, Chen D, Zheng H, Jiang D, Xu L, Bao C, Cao G, Fan W. Identification of invasion-metastasis-associated microRNAs in hepatocellular carcinoma based on bioinformatic analysis and experimental validation. J Transl Med 2018;16:266. [PMID: 30268144 DOI: 10.1186/s12967-018-1639-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 7.5] [Reference Citation Analysis]
86 Rattan P, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma. Liver Transpl. 2020;26:1316-1327. [PMID: 32564483 DOI: 10.1002/lt.25828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
87 Luo Y, Liu F, Han S, Qi Y, Hu X, Zhou C, Liang H, Zhang Z. Autophagy-Related Gene Pairs Signature for the Prognosis of Hepatocellular Carcinoma. Front Mol Biosci 2021;8:670241. [PMID: 34095224 DOI: 10.3389/fmolb.2021.670241] [Reference Citation Analysis]
88 Li S, Yao J, Xie M, Liu Y, Zheng M. Exosomal miRNAs in hepatocellular carcinoma development and clinical responses. J Hematol Oncol 2018;11:54. [PMID: 29642941 DOI: 10.1186/s13045-018-0579-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
89 Yuan XX, Zhu HJ, Pan H, Chen S, Liu ZY, Li Y, Wang LJ, Lu L, Yang HB, Gong FY. Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients. World J Gastroenterol 2019; 25(14): 1741-1752 [PMID: 31011258 DOI: 10.3748/wjg.v25.i14.1741] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
90 Li X, Zhou Y, Yang L, Ma Y, Peng X, Yang S, Li H, Liu J. LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma. J Cell Physiol. 2020;235:3402-3413. [PMID: 31549407 DOI: 10.1002/jcp.29230] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
91 Matsuda M, Seki E. Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis. Semin Liver Dis 2020;40:307-20. [PMID: 32242330 DOI: 10.1055/s-0040-1708876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
92 Duan T, Sun W, Zhang M, Ge J, He Y, Zhang J, Zheng Y, Yang W, Shen HM, Yang J, Zhu X, Yu P. Dietary restriction protects against diethylnitrosamine-induced hepatocellular tumorigenesis by restoring the disturbed gene expression profile. Sci Rep 2017;7:43745. [PMID: 28262799 DOI: 10.1038/srep43745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
93 Zecca A, Barili V, Canetti D, Regina V, Olivani A, Carone C, Capizzuto V, Zerbato B, Trenti T, Dalla Valle R, Ferrari C, Cariani E, Missale G. Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma. Cancer Immunol Immunother 2020;69:1589-603. [PMID: 32307580 DOI: 10.1007/s00262-020-02561-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
94 Jiang B, Yan XF, Zhang JH. Meta-analysis of laparoscopic versus open liver resection for hepatocellular carcinoma. Hepatol Res 2018;48:635-63. [PMID: 29330919 DOI: 10.1111/hepr.13061] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
95 Jia C, Dai C, Wang H, Wan Y, Qiao Y, Xu F, Peng S, Zhao Y, Zhao C, Zhao L. Differential Effects of Three Techniques for Hepatic Vascular Exclusion during Resection for Liver Cirrhosis on Hepatic Ischemia-Reperfusion Injury in Rats. Gastroenterol Res Pract 2018;2018:5309286. [PMID: 29507582 DOI: 10.1155/2018/5309286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
96 Xu Y, Guo Q, Wei L. The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5096. [PMID: 34680245 DOI: 10.3390/cancers13205096] [Reference Citation Analysis]
97 Scaglione S, Adams W, Caines A, Devlin P, Mittal S, Singal AG, Parikh ND. Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma. Dig Dis Sci. 2020;65:1669-1678. [PMID: 31643036 DOI: 10.1007/s10620-019-05890-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
98 Fujiwara N, Hoshida Y. Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. Semin Liver Dis 2019;39:153-62. [PMID: 30912093 DOI: 10.1055/s-0039-1681031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
99 Dou CZ, Liu YF, Zhang LL, Chen SH, Hu CY, Liu Y, Zhao YT. Polyphenols from Broussonetia papyrifera Induce Apoptosis of HepG2 Cells via Inactivation of ERK and AKT Signaling Pathways. Evid Based Complement Alternat Med 2021;2021:8841706. [PMID: 33884026 DOI: 10.1155/2021/8841706] [Reference Citation Analysis]
100 Zhu M, Lu T, Jia Y, Luo X, Gopal P, Li L, Odewole M, Renteria V, Singal AG, Jang Y, Ge K, Wang SC, Sorouri M, Parekh JR, MacConmara MP, Yopp AC, Wang T, Zhu H. Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease. Cell 2019;177:608-621.e12. [PMID: 30955891 DOI: 10.1016/j.cell.2019.03.026] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 25.7] [Reference Citation Analysis]
101 Chai Y, Zhao M. iTRAQ-Based Quantitative Proteomic Analysis of the Inhibitory Effects of Polysaccharides from Viscum coloratum (Kom.) Nakai on HepG2 Cells. Sci Rep 2017;7:4596. [PMID: 28676664 DOI: 10.1038/s41598-017-04417-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
102 Wang M, Yu F, Li P. Circular RNAs: Characteristics, Function and Clinical Significance in Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E258. [PMID: 30072625 DOI: 10.3390/cancers10080258] [Cited by in Crossref: 54] [Cited by in F6Publishing: 62] [Article Influence: 13.5] [Reference Citation Analysis]
103 Yang B, Feng X, Liu H, Tong R, Wu J, Li C, Yu H, Chen Y, Cheng Q, Chen J, Cai X, Wu W, Lu Y, Hu J, Liang K, Lv Z, Zheng S. High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma. Oncogene. 2020;39:6529-6543. [PMID: 32917956 DOI: 10.1038/s41388-020-01450-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
104 Gaba RC, Elkhadragy L, Boas FE, Chaki S, Chen HH, El-Kebir M, Garcia KD, Giurini EF, Guzman G, LoBianco FV, Neto MF, Newson JL, Qazi A, Regan M, Rund LA, Schwind RM, Stewart MC, Thomas FM, Whiteley HE, Wu J, Schook LB, Schachtschneider KM. Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation. Oncotarget 2020;11:2686-701. [PMID: 32733642 DOI: 10.18632/oncotarget.27647] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
105 Uche-Anya E, Anyane-Yeboa A, Berzin TM, Ghassemi M, May FP. Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity. Gut 2022:gutjnl-2021-326271. [PMID: 35688612 DOI: 10.1136/gutjnl-2021-326271] [Reference Citation Analysis]
106 Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, Taouli B, Chung RT, Hoshida Y. Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clin Transl Gastroenterol 2017;8:e101. [PMID: 28640287 DOI: 10.1038/ctg.2017.26] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 12.8] [Reference Citation Analysis]
107 Kim NJ, Magee C, Cummings C, Park H, Khalili M. Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population. Hepatol Commun 2018;2:1274-83. [PMID: 30288480 DOI: 10.1002/hep4.1246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
108 Zhou C, Sun Y, Guo S, Chen X, Bao G, Wang J. Wls Expression Correlates with Tumor Differentiation and TNM Stage in Hepatocellular Carcinoma. Dig Dis Sci 2018;63:166-72. [DOI: 10.1007/s10620-017-4823-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
109 Lingiah VA, Niazi M, Olivo R, Paterno F, Guarrera JV, Pyrsopoulos NT. Liver Transplantation Beyond Milan Criteria. J Clin Transl Hepatol 2020;8:69-75. [PMID: 32274347 DOI: 10.14218/JCTH.2019.00050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
110 Kuruvilla SP, Tiruchinapally G, ElAzzouny M, ElSayed ME. N-Acetylgalactosamine-Targeted Delivery of Dendrimer-Doxorubicin Conjugates Influences Doxorubicin Cytotoxicity and Metabolic Profile in Hepatic Cancer Cells. Adv Healthc Mater 2017;6. [PMID: 28085993 DOI: 10.1002/adhm.201601046] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
111 Hernaez R, El-Serag HB. Hepatocellular carcinoma surveillance: The road ahead. Hepatology 2017;65:771-3. [PMID: 27943335 DOI: 10.1002/hep.28983] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
112 Xia Y, Zhen L, Li H, Wang S, Chen S, Wang C, Yang X. MIRLET7BHG promotes hepatocellular carcinoma progression by activating hepatic stellate cells through exosomal SMO to trigger Hedgehog pathway. Cell Death Dis 2021;12:326. [PMID: 33771969 DOI: 10.1038/s41419-021-03494-1] [Reference Citation Analysis]
113 Li JF, Zheng EQ, Xie M. Association between rs738409 polymorphism in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and hepatocellular carcinoma susceptibility: Evidence from case-control studies. Gene 2019;685:143-8. [PMID: 30403964 DOI: 10.1016/j.gene.2018.11.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
114 Subhapradha N, Shanmugam V, Shanmugam A. Chitosan nanoparticles from marine squid protect liver cells against N -diethylnitrosoamine-induced hepatocellular carcinoma. Carbohydrate Polymers 2017;171:18-26. [DOI: 10.1016/j.carbpol.2017.04.097] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
115 Lin Y, Zhu J, Zhang J, Dai J, Liu S, Arroyo A, Rose M, Singal AG, Parikh ND, Lubman DM. Glycopeptides with Sialyl Lewis Antigen in Serum Haptoglobin as Candidate Biomarkers for Nonalcoholic Steatohepatitis Hepatocellular Carcinoma Using a Higher-Energy Collision-Induced Dissociation Parallel Reaction Monitoring-Mass Spectrometry Method. ACS Omega. [DOI: 10.1021/acsomega.2c02600] [Reference Citation Analysis]
116 Kim MN, Han K, Yoo J, Hwang SG, Ahn SH. Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver. Aliment Pharmacol Ther 2022;55:97-107. [PMID: 34820871 DOI: 10.1111/apt.16706] [Reference Citation Analysis]
117 Yao R, Zou H, Liao W. Prospect of Circular RNA in Hepatocellular Carcinoma: A Novel Potential Biomarker and Therapeutic Target. Front Oncol. 2018;8:332. [PMID: 30191143 DOI: 10.3389/fonc.2018.00332] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
118 Si WK, Chung JW, Cho J, Baeg JY, Jang ES, Yoon H, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Lim S, Kim JW. Predictors of Increased Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes. PLoS One 2016;11:e0158066. [PMID: 27359325 DOI: 10.1371/journal.pone.0158066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
119 Zhang W, Chen K, Tian W, Zhang Q, Sun L, Wang Y, Liu M, Zhang Q. A Novel and Robust Prognostic Model for Hepatocellular Carcinoma Based on Enhancer RNAs-Regulated Genes. Front Oncol 2022;12:849242. [PMID: 35646665 DOI: 10.3389/fonc.2022.849242] [Reference Citation Analysis]
120 Zhang C, Yang H, Pan L, Zhao G, Zhang R, Zhang T, Xiao Z, Tong Y, Zhang Y, Hu R, Pandol SJ, Han YP. Hepatitis B Virus X Protein (HBx) Suppresses Transcription Factor EB (TFEB) Resulting in Stabilization of Integrin Beta 1 (ITGB1) in Hepatocellular Carcinoma Cells. Cancers (Basel) 2021;13:1181. [PMID: 33803301 DOI: 10.3390/cancers13051181] [Reference Citation Analysis]
121 Wallace MC, Preen DB, Short MW, Adams LA, Jeffrey GP. Hepatocellular carcinoma in Australia 1982-2014: Increasing incidence and improving survival. Liver Int 2019;39:522-30. [PMID: 30230194 DOI: 10.1111/liv.13966] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
122 Shi K, Liu Y, Wang X, Li Y, Zhang Q, Hu Y, Ran C, Huang Y, Hou J, Wang X. Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis. Evid Based Complement Alternat Med 2020;2020:8826091. [PMID: 33178324 DOI: 10.1155/2020/8826091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Siddiqui IA, Kirks RC, Latouche EL, DeWitt MR, Swet JH, Baker EH, Vrochides D, Iannitti DA, Davalos RV, McKillop IH. High-Frequency Irreversible Electroporation: Safety and Efficacy of Next-Generation Irreversible Electroporation Adjacent to Critical Hepatic Structures. Surg Innov. 2017;24:276-283. [PMID: 28492356 DOI: 10.1177/1553350617692202] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
124 Schönfeld I, Kraywinkel K. Epidemiologie des hepatozellulären Karzinoms in Deutschland. Onkologe 2018;24:653-8. [DOI: 10.1007/s00761-018-0438-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
125 Zhou L, Du Y, Kong L, Zhang X, Chen Q. Identification of molecular target genes and key pathways in hepatocellular carcinoma by bioinformatics analysis. Onco Targets Ther 2018;11:1861-9. [PMID: 29670361 DOI: 10.2147/OTT.S156737] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
126 Liu H, Xue L, Song C, Liu F, Jiang T, Yang X. Overexpression of circular RNA circ_001569 indicates poor prognosis in hepatocellular carcinoma and promotes cell growth and metastasis by sponging miR-411-5p and miR-432-5p. Biochemical and Biophysical Research Communications 2018;503:2659-65. [DOI: 10.1016/j.bbrc.2018.08.020] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
127 Ispas S, So S, Toy M. Barriers to Disease Monitoring and Liver Cancer Surveillance Among Patients with Chronic Hepatitis B in the United States. J Community Health 2019;44:610-25. [PMID: 30539329 DOI: 10.1007/s10900-018-00604-7] [Reference Citation Analysis]
128 Lin P, He RQ, Dang YW, Wen DY, Ma J, He Y, Chen G, Yang H. An autophagy-related gene expression signature for survival prediction in multiple cohorts of hepatocellular carcinoma patients. Oncotarget 2018;9:17368-95. [PMID: 29707114 DOI: 10.18632/oncotarget.24089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
129 Saviano A, Roehlen N, Virzì A, Roca Suarez AA, Hoshida Y, Lupberger J, Baumert TF. Stromal and Immune Drivers of Hepatocarcinogenesis. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 317-31. [DOI: 10.1007/978-3-030-21540-8_15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
130 Passi M, Zahler S. Mechano-Signaling Aspects of Hepatocellular Carcinoma. J Cancer 2021;12:6411-21. [PMID: 34659531 DOI: 10.7150/jca.60102] [Reference Citation Analysis]
131 Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY) 2018;43:13-25. [PMID: 28647765 DOI: 10.1007/s00261-017-1209-1] [Cited by in Crossref: 208] [Cited by in F6Publishing: 192] [Article Influence: 52.0] [Reference Citation Analysis]
132 Santos SGRD, Mattos AA, Guimarães MM, Boger BS, Coral GP. Alcohol Consumption Influences Clinical Outcome in Patients Admitted to a Referral Center for Liver Disease. Ann Hepatol 2018;17:470-5. [PMID: 29735785 DOI: 10.5604/01.3001.0011.7391] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
133 Huang DQ, Singal AG, Kono Y, Tan DJ, El-serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism 2022. [DOI: 10.1016/j.cmet.2022.05.003] [Reference Citation Analysis]
134 Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JH, de Guevara LL, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol. 2016;65:1140-1147. [PMID: 27469901 DOI: 10.1016/j.jhep.2016.07.020] [Cited by in Crossref: 136] [Cited by in F6Publishing: 138] [Article Influence: 22.7] [Reference Citation Analysis]
135 Zhang P, Liu Q, Yuan M, Wang L. Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis. Infect Agent Cancer 2018;13:30. [PMID: 30181772 DOI: 10.1186/s13027-018-0203-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
136 Liu Z, Chen M, Zhao R, Huang Y, Liu F, Li B, Qin Y. CAF-induced placental growth factor facilitates neoangiogenesis in hepatocellular carcinoma. Acta Biochim Biophys Sin (Shanghai) 2020;52:18-25. [PMID: 31828297 DOI: 10.1093/abbs/gmz134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
137 Alavi M, Janjua NZ, Chong M, Grebely J, Aspinall EJ, Innes H, Valerio H, Hajarizadeh B, Hayes PC, Krajden M. Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. J Viral Hepat. 2018;25:473-481. [PMID: 29194861 DOI: 10.1111/jvh.12837] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
138 El-Serag HB. Hospitalizations for Chronic Liver Disease: Time to Intervene at Multiple Levels. Gastroenterology 2018;155:607-9. [PMID: 30076836 DOI: 10.1053/j.gastro.2018.07.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
139 Gong B, Kao Y, Zhang C, Sun F, Zhao H. Systematic Investigation of Scutellariae Barbatae Herba for Treating Hepatocellular Carcinoma Based on Network Pharmacology. Evid Based Complement Alternat Med 2018;2018:4365739. [PMID: 30584453 DOI: 10.1155/2018/4365739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
140 Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood) 2020;245:96-108. [PMID: 31924111 DOI: 10.1177/1535370219898141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
141 Zhang J, Chang Y, Xu L, Qin L. Elevated expression of circular RNA circ_0008450 predicts dismal prognosis in hepatocellular carcinoma and regulates cell proliferation, apoptosis, and invasion via sponging miR-548p. J Cell Biochem 2019;120:9487-94. [PMID: 30556306 DOI: 10.1002/jcb.28224] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
142 Lee J, Cho Y, Park S, Kim JW, Lee IJ. Skeletal Muscle Depletion Predicts the Prognosis of Patients With Hepatocellular Carcinoma Treated With Radiotherapy. Front Oncol 2019;9:1075. [PMID: 31681607 DOI: 10.3389/fonc.2019.01075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
143 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis. J Cancer 2017;8:378-87. [PMID: 28261338 DOI: 10.7150/jca.16786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
144 Khalaf N, Ying J, Mittal S, Temple S, Kanwal F, Davila J, El-Serag HB. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clin Gastroenterol Hepatol 2017;15:273-281.e1. [PMID: 27521507 DOI: 10.1016/j.cgh.2016.07.033] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 9.8] [Reference Citation Analysis]
145 Gadiparthi C, Yoo ER, Are VS, Charilaou P, Kim D, Cholankeril G, Pitchumoni C, Ahmed A. Hepatocellular carcinoma is leading in cancer-related disease burden among hospitalized baby boomers. Ann Hepatol 2019;18:679-84. [PMID: 31164267 DOI: 10.1016/j.aohep.2019.04.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
146 Li MX, Zhao H, Bi XY, Li ZY, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Cai JQ. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort. Hepatol Res. 2017;47:731-741. [PMID: 27558521 DOI: 10.1111/hepr.12796] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
147 Mazzolini G, Sowa J, Canbay A. Cell death mechanisms in human chronic liver diseases: a far cry from clinical applicability. Clinical Science 2016;130:2121-38. [DOI: 10.1042/cs20160035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
148 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
149 Ruan J, Zheng H, Rong X, Rong X, Zhang J, Fang W, Zhao P, Luo R. Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients. Mol Cancer 2016;15:17. [PMID: 26896959 DOI: 10.1186/s12943-016-0503-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
150 Katoh M. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). Int J Mol Med 2018;42:713-25. [PMID: 29786110 DOI: 10.3892/ijmm.2018.3689] [Cited by in Crossref: 19] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
151 Onyirioha K, Mittal S, G Singal A. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol 2020;7:HEP25. [PMID: 32774835 DOI: 10.2217/hep-2020-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Wu L, Yang W, Zhang Y, Du X, Jin N, Chen W, Li H, Zhang S, Xie B. Elevated Serum Uric Acid is Associated With Poor Survival in Advanced HCC Patients and Febuxostat Improves Prognosis in HCC Rats. Front Pharmacol 2021;12:778890. [PMID: 34858193 DOI: 10.3389/fphar.2021.778890] [Reference Citation Analysis]
153 Ioannou GN, Tang W, Beste LA, Tincopa MA, Su GL, Van T, Tapper EB, Singal AG, Zhu J, Waljee AK. Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. JAMA Netw Open. 2020;3:e2015626. [PMID: 32870314 DOI: 10.1001/jamanetworkopen.2020.15626] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
154 Wang M, Shen J, Herrera H, Singal A, Swindell C, Renquan L, Mehta A. Biomarker analysis of fucosylated kininogen through depletion of lectin reactive heterophilic antibodies in hepatocellular carcinoma. J Immunol Methods 2018;462:59-64. [PMID: 30144410 DOI: 10.1016/j.jim.2018.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
155 Lambrecht C, Libbrecht L, Sagaert X, Pauwels P, Hoorne Y, Crowther J, Louis JV, Sents W, Sablina A, Janssens V. Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo. Oncogene 2018;37:544-52. [DOI: 10.1038/onc.2017.350] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
156 Shankaraiah RC, Gramantieri L, Fornari F, Sabbioni S, Callegari E, Negrini M. Animal Models of Hepatocellular Carcinoma Prevention. Cancers (Basel) 2019;11:E1792. [PMID: 31739536 DOI: 10.3390/cancers11111792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
157 Schütte K, Balbisi F, Malfertheiner P. Prevention of Hepatocellular Carcinoma. Gastrointest Tumors 2016;3:37-43. [PMID: 27722155 DOI: 10.1159/000446680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
158 Zhang Z, Yang L, Yao X, Yang M, Li G. LncRNA-ZNF281 Interacts with miR-539 to Promote Hepatocellular Carcinoma Cell Invasion and Migration. Cancer Biother Radiopharm 2020;35:137-42. [PMID: 32073896 DOI: 10.1089/cbr.2019.3008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Cui Y, Sun D, Song R, Zhang S, Liu X, Wang Y, Meng F, Lan Y, Han J, Pan S, Liang S, Zhang B, Guo H, Liu Y, Lu Z, Liu L. Upregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis. J Cell Physiol 2019;234:22623-34. [PMID: 31106426 DOI: 10.1002/jcp.28828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
160 Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther 2021;6:128. [PMID: 33776057 DOI: 10.1038/s41392-021-00507-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
161 Di Costanzo GG, Casadei Gardini A, Marisi G, Foschi FG, Scartozzi M, Granata R, Faloppi L, Cascinu S, Silvestris N, Brunetti O, Palmieri VO, Ercolani G, Tortora R. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targ Oncol 2017;12:795-803. [DOI: 10.1007/s11523-017-0522-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
162 Cui Y, Liang S, Zhang S, Zhang C, Zhao Y, Wu D, Wang J, Song R, Wang J, Yin D, Liu Y, Pan S, Liu X, Wang Y, Han J, Meng F, Zhang B, Guo H, Lu Z, Liu L. ABCA8 is regulated by miR-374b-5p and inhibits proliferation and metastasis of hepatocellular carcinoma through the ERK/ZEB1 pathway. J Exp Clin Cancer Res 2020;39:90. [PMID: 32430024 DOI: 10.1186/s13046-020-01591-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
163 Di Poto C, Ferrarini A, Zhao Y, Varghese RS, Tu C, Zuo Y, Wang M, Nezami Ranjbar MR, Luo Y, Zhang C, Desai CS, Shetty K, Tadesse MG, Ressom HW. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery. Cancer Epidemiol Biomarkers Prev. 2017;26:675-683. [PMID: 27913395 DOI: 10.1158/1055-9965.epi-16-0366] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
164 Pocha C, Xie C. Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies? Transl Gastroenterol Hepatol 2019;4:72. [PMID: 31728429 DOI: 10.21037/tgh.2019.09.01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
165 Yao Z, Xu R, Yuan L, Xu M, Zhuang H, Li Y, Zhang Y, Lin N. Circ_0001955 facilitates hepatocellular carcinoma (HCC) tumorigenesis by sponging miR-516a-5p to release TRAF6 and MAPK11. Cell Death Dis 2019;10:945. [PMID: 31822654 DOI: 10.1038/s41419-019-2176-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
166 Li YT, Wu HL, Liu CJ. Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. Int J Mol Sci 2021;22:9380. [PMID: 34502289 DOI: 10.3390/ijms22179380] [Reference Citation Analysis]
167 Li M, Zhao H, Bi X, Li Z, Huang Z, Han Y, Zhou J, Zhao J, Zhang Y, Wei W, Zhao D, Cai J. Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma. Tumor Biol 2016;37:9301-10. [DOI: 10.1007/s13277-016-4794-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
168 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
169 Li Z, Zhang J, Liu X, Li S, Wang Q, Di Chen, Hu Z, Yu T, Ding J, Li J, Yao M, Fan J, Huang S, Gao Q, Zhao Y, He X. The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma. Nat Commun 2018;9:1572. [PMID: 29679004 DOI: 10.1038/s41467-018-04006-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 82] [Article Influence: 17.8] [Reference Citation Analysis]
170 Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, Gwak GY. Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. Int J Epidemiol 2020;49:1562-71. [PMID: 32725117 DOI: 10.1093/ije/dyaa089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
171 Zheng Y, Liu Y, Zhao S, Zheng Z, Shen C, An L, Yuan Y. Large-scale analysis reveals a novel risk score to predict overall survival in hepatocellular carcinoma. Cancer Manag Res 2018;10:6079-96. [PMID: 30538557 DOI: 10.2147/CMAR.S181396] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
172 Fang KC, Kao WY, Su CW, Chen PC, Lee PC, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. Liver Cancer. 2018;7:335-358. [PMID: 30488023 DOI: 10.1159/000487407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
173 Yamao T, Imai K, Yamashita Y, Kaida T, Nakagawa S, Mima K, Hashimoto D, Chikamoto A, Ishiko T, Baba H. Surgical treatment strategy for hepatocellular carcinoma in patients with impaired liver function: hepatic resection or radiofrequency ablation? HPB 2018;20:244-50. [DOI: 10.1016/j.hpb.2017.08.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
174 Castro-Gil MP, Sánchez-Rodríguez R, Torres-Mena JE, López-Torres CD, Quintanar-Jurado V, Gabiño-López NB, Villa-Treviño S, Del-Pozo-Jauner L, Arellanes-Robledo J, Pérez-Carreón JI. Enrichment of progenitor cells by 2-acetylaminofluorene accelerates liver carcinogenesis induced by diethylnitrosamine in vivo. Mol Carcinog 2021;60:377-90. [PMID: 33765333 DOI: 10.1002/mc.23298] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Wang F, Numata K, Nihonmatsu H, Okada M, Maeda S. Application of new ultrasound techniques for focal liver lesions. J Med Ultrason (2001) 2020;47:215-37. [PMID: 31950396 DOI: 10.1007/s10396-019-01001-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
176 Hughes DM, Berhane S, Emily de Groot CA, Toyoda H, Tada T, Kumada T, Satomura S, Nishida N, Kudo M, Kimura T, Osaki Y, Kolamunage-Dona R, Amoros R, Bird T, Garcίa-Fiñana M, Johnson P. Serum Levels of α-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021;19:162-170.e4. [PMID: 32389887 DOI: 10.1016/j.cgh.2020.04.084] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
177 Hu XX, Yang ZX, Liang HY, Ding Y, Grimm R, Fu CX, Liu H, Yan X, Ji Y, Zeng MS, Rao SX. Whole-tumor MRI histogram analyses of hepatocellular carcinoma: Correlations with Ki-67 labeling index. J Magn Reson Imaging 2017;46:383-92. [PMID: 27862582 DOI: 10.1002/jmri.25555] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
178 Xu L, Tong T, Wang Z, Qiang Y, Ma F, Ma X. Identification of Hub Genes and Analysis of Prognostic Values in Hepatocellular Carcinoma by Bioinformatics Analysis. Am J Med Sci 2020;359:226-34. [PMID: 32200915 DOI: 10.1016/j.amjms.2020.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
179 Yang X, Cai JB, Peng R, Wei CY, Lu JC, Gao C, Shen ZZ, Zhang PF, Huang XY, Ke AW, Shi GM, Fan J. The long noncoding RNA NORAD enhances the TGF-β pathway to promote hepatocellular carcinoma progression by targeting miR-202-5p. J Cell Physiol 2019;234:12051-60. [PMID: 30537113 DOI: 10.1002/jcp.27869] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
180 Elnaggar MH, Abushouk AI, Hassan AHE, Lamloum HM, Benmelouka A, Moatamed SA, Abd-Elmegeed H, Attia S, Samir A, Amr N, Johar D, Zaky S. Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma. Semin Cancer Biol 2021;69:91-9. [PMID: 31421265 DOI: 10.1016/j.semcancer.2019.08.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
181 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett 2017;14:1637-47. [PMID: 28789390 DOI: 10.3892/ol.2017.6287] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
182 Marquardt JU, Nguyen-Tat M, Galle PR, Wörns MA. Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. Visc Med 2016;32:110-5. [PMID: 27413728 DOI: 10.1159/000445407] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
183 de Guevara LL, Dagher L, Arruda VM, Nakajima K, Kudo M. Sorafenib treatment by Child-Pugh score in Latin American patients with hepatocellular carcinoma. Future Oncol 2020;16:2511-20. [PMID: 32783460 DOI: 10.2217/fon-2020-0323] [Reference Citation Analysis]
184 Qiu J, Lu W, Yu N, Yang G, Li Y, Huang Z, Li J, Li K, Xu H, Chen S, Zeng X, Liu H. HabibTM 4X-assisted resection versus clamp-crush resection for hepatocellular carcinoma: a propensity-matching study. Oncotarget 2017;8:4218-27. [PMID: 27965468 DOI: 10.18632/oncotarget.13906] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
185 Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71. [PMID: 28337405 DOI: 10.1007/s11901-017-0336-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
186 Chen QL, Yan Q, Feng KL, Xie CF, Fang CK, Wang JN, Liu LH, Li Y, Zhong C. Using Integrated Bioinformatics Analysis to Identify Abnormally Methylated Differentially Expressed Genes in Hepatocellular Carcinoma. Int J Gen Med 2021;14:805-23. [PMID: 33732011 DOI: 10.2147/IJGM.S294505] [Reference Citation Analysis]
187 Debes JD, Chan AJ, Balderramo D, Kikuchi L, Gonzalez Ballerga E, Prieto JE, Tapias M, Idrovo V, Davalos MB, Cairo F. Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. Liver Int. 2018;38:136-143. [PMID: 28640517 DOI: 10.1111/liv.13502] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
188 Gillet JP, Andersen JB, Madigan JP, Varma S, Bagni RK, Powell K, Burgan WE, Wu CP, Calcagno AM, Ambudkar SV. A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Mol Pharmacol. 2016;89:263-272. [PMID: 26668215 DOI: 10.1124/mol.115.101360] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
189 Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, Mo F, Lai P, Chan SL, Tada T, Toyoda H, Kumada T. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017;116:441-447. [PMID: 28081537 DOI: 10.1038/bjc.2016.422] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
190 Gündüz MK, Bolat M, Kaymak G, Berikten D, Köse DA. Therapeutic Effects of Newly Synthesized Boron Compounds (BGM and BGD) on Hepatocellular Carcinoma. Biol Trace Elem Res 2021. [PMID: 33634364 DOI: 10.1007/s12011-021-02647-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 Li L, Piontek K, Ishida M, Fausther M, Dranoff JA, Fu R, Mezey E, Gould SJ, Fordjour FK, Meltzer SJ, Sirica AE, Selaru FM. Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology 2017;65:501-14. [PMID: 27474881 DOI: 10.1002/hep.28735] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 14.4] [Reference Citation Analysis]
192 Zheng J, Wu D, Wang L, Qu F, Cheng D, Liu X. mir-182-5p Regulates Cell Growth of Liver Cancer via Targeting RCAN1. Gastroenterol Res Pract 2021;2021:6691305. [PMID: 33959160 DOI: 10.1155/2021/6691305] [Reference Citation Analysis]
193 Affo S, Yu LX, Schwabe RF. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annu Rev Pathol 2017;12:153-86. [PMID: 27959632 DOI: 10.1146/annurev-pathol-052016-100322] [Cited by in Crossref: 183] [Cited by in F6Publishing: 189] [Article Influence: 30.5] [Reference Citation Analysis]
194 McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:4-13. [PMID: 32319693 DOI: 10.1002/hep.31288] [Cited by in Crossref: 254] [Cited by in F6Publishing: 193] [Article Influence: 254.0] [Reference Citation Analysis]
195 Uchikawa S, Kawaoka T, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Miki D, Imamura M, Aikata H. The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis. J Med Ultrason (2001) 2022. [PMID: 35524897 DOI: 10.1007/s10396-022-01210-w] [Reference Citation Analysis]
196 Zhao G, Song Y, Dong L, Shi H, Li H, Yang L, Wang J. Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3β/Wnt/β-catenin signaling. Biochem Biophys Res Commun 2019;517:722-8. [PMID: 31395338 DOI: 10.1016/j.bbrc.2019.07.122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
197 Galicia-Moreno M, Silva-Gomez JA, Lucano-Landeros S, Santos A, Monroy-Ramirez HC, Armendariz-Borunda J. Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models. Can J Gastroenterol Hepatol 2021;2021:8837811. [PMID: 33728291 DOI: 10.1155/2021/8837811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
198 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
199 Jędrzak A, Grześkowiak BF, Golba K, Coy E, Synoradzki K, Jurga S, Jesionowski T, Mrówczyński R. Magnetite Nanoparticles and Spheres for Chemo- and Photothermal Therapy of Hepatocellular Carcinoma in vitro. Int J Nanomedicine 2020;15:7923-36. [PMID: 33116509 DOI: 10.2147/IJN.S257142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
200 Wang M, Xi D, Ning Q. Virus-induced hepatocellular carcinoma with special emphasis on HBV. Hepatol Int. 2017;11:171-180. [PMID: 28097530 DOI: 10.1007/s12072-016-9779-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
201 Yohanathan L, Heimbach JK. The Impact of Allocation Changes on Patients with Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:657-63. [DOI: 10.1016/j.cld.2020.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
202 Yu Y, Han S, Li M, Song Y, Qi F. Circ_0004913 sponges miR-1290 and regulates FOXC1 to inhibit the proliferation of hepatocellular carcinoma. Cancer Cell Int 2020;20. [DOI: 10.1186/s12935-020-01521-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Rey S, Quintavalle C, Burmeister K, Calabrese D, Schlageter M, Quagliata L, Cathomas G, Diebold J, Molinolo A, Heim MH, Terracciano LM, Matter MS. Liver damage and senescence increases in patients developing hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:1480-6. [PMID: 28052383 DOI: 10.1111/jgh.13717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
204 Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment. Int J Mol Sci 2019;20:E605. [PMID: 30704150 DOI: 10.3390/ijms20030605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
205 Feng Z, Marrero JA, Khaderi S, Singal AG, Kanwal F, Loo N, Beretta L, Ning J, El-Serag HB. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol 2019;114:530-2. [PMID: 30699099 DOI: 10.14309/ajg.0000000000000068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
206 Moreno FS, Heidor R, Pogribny IP. Nutritional Epigenetics and the Prevention of Hepatocellular Carcinoma with Bioactive Food Constituents. Nutrition and Cancer 2016;68:719-33. [DOI: 10.1080/01635581.2016.1180410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
207 Hu W, Feng H, Xu X, Huang X, Huang X, Chen W, Hao L, Xia W. Long noncoding RNA FOXD2-AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR-206/MAP3K1 axis. Cancer Med 2020;9:5620-31. [PMID: 32558350 DOI: 10.1002/cam4.3204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
208 Désert R, Mebarki S, Desille M, Sicard M, Lavergne E, Renaud S, Bergeat D, Sulpice L, Perret C, Turlin B, Clément B, Musso O. "Fibrous nests" in human hepatocellular carcinoma express a Wnt-induced gene signature associated with poor clinical outcome. Int J Biochem Cell Biol 2016;81:195-207. [PMID: 27545991 DOI: 10.1016/j.biocel.2016.08.017] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
209 Ding K, Liao Y, Gong D, Zhao X, Ji W. Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2018;502:194-201. [DOI: 10.1016/j.bbrc.2018.05.143] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
210 Deng Z, Xu XY, Yunita F, Zhou Q, Wu YR, Hu YX, Wang ZQ, Tian XF. Synergistic anti-liver cancer effects of curcumin and total ginsenosides. World J Gastrointest Oncol 2020; 12(10): 1091-1103 [PMID: 33133379 DOI: 10.4251/wjgo.v12.i10.1091] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
211 De Toni EN, Schlesinger-Raab A, Fuchs M, Schepp W, Ehmer U, Geisler F, Ricke J, Paprottka P, Friess H, Werner J, Gerbes AL, Mayerle J, Engel J. Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut 2020;69:168-76. [PMID: 30878947 DOI: 10.1136/gutjnl-2018-318193] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 16.5] [Reference Citation Analysis]
212 Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Reference Citation Analysis]
213 Zhang R, Li Y, Yu H, Liu L, Zhu C, Zuo S, Chen Z. An aberrant DNA methylation signature for predicting hepatocellular carcinoma. Ann Transl Med 2020;8:1667. [PMID: 33490179 DOI: 10.21037/atm-20-7804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
214 Benhammou JN, Lin J, Hussain SK, El-Kabany M. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Res 2020;6:35. [PMID: 32685690 DOI: 10.20517/2394-5079.2020.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
215 Nhu QM, Knowles H, Pockros PJ, Frenette CT. Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Respirol 2016; 6(3): 69-75 [PMID: 27904836 DOI: 10.5320/wjr.v6.i3.69] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
216 Liu D, Kang H, Gao M, Jin L, Zhang F, Chen D, Li M, Xiao L. Exosome-transmitted circ_MMP2 promotes hepatocellular carcinoma metastasis by upregulating MMP2. Mol Oncol 2020;14:1365-80. [PMID: 31944556 DOI: 10.1002/1878-0261.12637] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
217 Wani NA, Zhang B, Teng KY, Barajas JM, Motiwala T, Hu P, Yu L, Brüschweiler R, Ghoshal K, Jacob ST. Reprograming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis. Mol Cancer Res 2018;16:256-68. [PMID: 29187559 DOI: 10.1158/1541-7786.MCR-17-0304] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
218 Beal EW, Kearney JF, Chakedis JM, James Hanje A, Conteh LF, Black SM, Washburn K, Dittmar KM, Pawlik TM, Dillhoff MR, Schmidt CR. Interval Magnetic Resonance Imaging: an Alternative to Guidelines for Indeterminate Nodules Discovered in the Cirrhotic Liver. J Gastrointest Surg 2017;21:1463-70. [PMID: 28550393 DOI: 10.1007/s11605-017-3454-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
219 Cheung PF, Yip CW, Ng LW, Lo KW, Chow C, Chan KF, Cheung TT, Cheung ST. Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line. Cancer Cell Int 2016;16:41. [PMID: 27279800 DOI: 10.1186/s12935-016-0322-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
220 Shi Y, Sun X, He X. Overexpression of Aristaless-Like Homeobox-4 Inhibits Proliferation, Invasion, and EMT in Hepatocellular Carcinoma Cells. Oncol Res 2017;25:11-8. [PMID: 28081728 DOI: 10.3727/096504016X14685034103833] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
221 Pan H, Tang L, Jiang H, Li X, Wang R, Gao J, Li Q. Enhanced expression of circ_0000267 in hepatocellular carcinoma indicates poor prognosis and facilitates cell progression by sponging miR-646. J Cell Biochem 2019. [PMID: 30719761 DOI: 10.1002/jcb.28411] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
222 Hong JH, Lee K, Kim J, Ahn KM. Prognosis of hepatocellular carcinoma metastasizing to the oral cavity. Maxillofac Plast Reconstr Surg 2021;43:9. [PMID: 33689049 DOI: 10.1186/s40902-021-00294-7] [Reference Citation Analysis]
223 Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther 2022. [PMID: 35514249 DOI: 10.1080/14737140.2022.2074404] [Reference Citation Analysis]
224 Ioannou GN, Green PK, Beste LA, Mun EJ, Kerr KF, Berry K. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol. 2018;69:1088-1098. [PMID: 30138686 DOI: 10.1016/j.jhep.2018.07.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 13.5] [Reference Citation Analysis]
225 Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2021;6:649-58. [PMID: 34087115 DOI: 10.1016/S2468-1253(21)00110-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Zhang X, Xu X, Ge G, Zang X, Shao M, Zou S, Zhang Y, Mao Z, Zhang J, Mao F, Qian H, Xu W. miR‑498 inhibits the growth and metastasis of liver cancer by targeting ZEB2. Oncol Rep 2019;41:1638-48. [PMID: 30592286 DOI: 10.3892/or.2018.6948] [Cited by in Crossref: 12] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
227 Zhang H, Spencer K, Burley SK, Zheng XFS. Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. Drug Discov Today 2021;26:1539-46. [PMID: 33561464 DOI: 10.1016/j.drudis.2021.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
228 Yasmin A, Regan DP, Schook LB, Gaba RC, Schachtschneider KM. Transcriptional regulation of alcohol induced liver fibrosis in a translational porcine hepatocellular carcinoma model. Biochimie 2021;182:73-84. [PMID: 33444661 DOI: 10.1016/j.biochi.2020.12.022] [Reference Citation Analysis]
229 Sojoodi M, Wei L, Erstad DJ, Yamada S, Fujii T, Hirschfield H, Kim RS, Lauwers GY, Lanuti M, Hoshida Y, Tanabe KK, Fuchs BC. Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma. Cancer Prev Res (Phila) 2020;13:497-508. [PMID: 32253266 DOI: 10.1158/1940-6207.CAPR-19-0383] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
230 Nishi Y, Aoki T, Shimizu T, Sato S, Matsumoto T, Shiraki T, Sakuraoka Y, Mori S, Iso Y, Ishizuka M, Kubota K. Significance of cytoplasmic expression of telomerase reverse transcriptase in patients with hepatocellular carcinoma undergoing liver resection. Mol Clin Oncol 2021;15:244. [PMID: 34650811 DOI: 10.3892/mco.2021.2406] [Reference Citation Analysis]
231 Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Canc Inst 2020;32:5. [PMID: 32372179 DOI: 10.1186/s43046-020-0016-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
232 Huang B, Tian ZF, Li LF, Fan Y, Yin HY, Li Y, Mao Q, You ZL. LHX3 is an advanced-stage prognostic biomarker and metastatic oncogene in hepatocellular carcinoma. Cancer Biomark 2019;26:31-9. [PMID: 31306102 DOI: 10.3233/CBM-182257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
233 Gao L, Wang KX, Zhou YZ, Fang JS, Qin XM, Du GH. Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation. Sci Rep 2018;8:624. [PMID: 29330507 DOI: 10.1038/s41598-017-18325-7] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 15.0] [Reference Citation Analysis]
234 Ciurea AM, Vere CC, Schenker M, Gheonea IA, Streba L, Săndulescu LD, Mehedinţeanu AM, Gheonea DI. Evaluation of Hepatocellular Carcinoma Patients: Interim Analysis of Cases from a Tertiary Referral Center in Craiova, Romania. Curr Health Sci J 2021;47:10-5. [PMID: 34211741 DOI: 10.12865/CHSJ.47.01.02] [Reference Citation Analysis]
235 Ortega JF, de Conti A, Tryndyak V, Furtado KS, Heidor R, Horst MA, Fernandes LH, Tavares PE, Pogribna M, Shpyleva S, Beland FA, Pogribny IP, Moreno FS. Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein. Oncotarget 2016;7:24339-47. [PMID: 27013579 DOI: 10.18632/oncotarget.8248] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
236 Abraldes JG, Burak KW. STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma? Hepatology 2016;64:13-5. [PMID: 26946464 DOI: 10.1002/hep.28537] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
237 Oh S, Jo Y, Jung S, Yoon S, Yoo KH. From genome sequencing to the discovery of potential biomarkers in liver disease. BMB Rep 2020;53:299-310. [DOI: 10.5483/bmbrep.2020.53.6.074] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
238 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
239 Kim HS, El-Serag HB. The Epidemiology of Hepatocellular Carcinoma in the USA. Curr Gastroenterol Rep. 2019;21:17. [PMID: 30976932 DOI: 10.1007/s11894-019-0681-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
240 Ma L, Jiang H, Xu X, Zhang C, Niu Y, Wang Z, Tao Y, Li Y, Cai F, Zhang X, Wang X, Yu Y. Tanshinone IIA mediates SMAD7-YAP interaction to inhibit liver cancer growth by inactivating the transforming growth factor beta signaling pathway. Aging (Albany NY) 2019;11:9719-37. [PMID: 31711043 DOI: 10.18632/aging.102420] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
241 Liu F, Liao Z, Song J, Yuan C, Liu Y, Zhang H, Pan Y, Zhang Z, Zhang B. Genome-wide screening diagnostic biomarkers and the construction of prognostic model of hepatocellular carcinoma. J Cell Biochem 2020;121:2582-94. [PMID: 31692036 DOI: 10.1002/jcb.29480] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
242 Quintavalle C, Hindupur SK, Quagliata L, Pallante P, Nigro C, Condorelli G, Andersen JB, Tagscherer KE, Roth W, Beguinot F, Heim MH, Ng CKY, Piscuoglio S, Matter MS. Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib. Cell Death Dis 2017;8:e3138. [PMID: 29072691 DOI: 10.1038/cddis.2017.512] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
243 Nishina S, Yamauchi A, Kawaguchi T, Kaku K, Goto M, Sasaki K, Hara Y, Tomiyama Y, Kuribayashi F, Torimura T, Hino K. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice. Cell Mol Gastroenterol Hepatol 2019;7:115-34. [PMID: 30510994 DOI: 10.1016/j.jcmgh.2018.08.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
244 Zeng G, Gill US, Kennedy PTF. Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis. Gut 2020;69:1907-12. [PMID: 32451325 DOI: 10.1136/gutjnl-2020-321627] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
245 Ge Z, Ma J, Qiao B, Wang Y, Zhang H, Gou W. Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality. Medicine (Baltimore) 2020;99:e21454. [PMID: 32769872 DOI: 10.1097/MD.0000000000021454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Cersosimo RJ. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. Am J Health Syst Pharm 2021;78:187-202. [PMID: 33211092 DOI: 10.1093/ajhp/zxaa365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Liu X, Zhang F, Liu Y, Fan Y, Wang K. Effects of total nocturnal sleep time and siesta on hepatocellular carcinoma risks in individuals with chronic HBV infection. Sleep Biol Rhythms 2018;16:99-105. [DOI: 10.1007/s41105-017-0131-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
248 Ghufran H, Azam M, Mehmood A, Butt H, Riazuddin S. Standardization of diethylnitrosamine-induced hepatocellular carcinoma rat model with time based molecular assessment. Exp Mol Pathol 2021;123:104715. [PMID: 34699901 DOI: 10.1016/j.yexmp.2021.104715] [Reference Citation Analysis]
249 Zheng C, Liu X, Chen L, Xu Z, Shao J. lncRNAs as prognostic molecular biomarkers in hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:59638-47. [PMID: 28938667 DOI: 10.18632/oncotarget.19559] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
250 Huang C, Fang M, Xiao X, Wang H, Gao Z, Ji J, Liu L, Gu E, Li Y, Wang M, Gao C. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study. Liver Int 2021. [PMID: 34679250 DOI: 10.1111/liv.15082] [Reference Citation Analysis]
251 Cagnin M, Biasiolo A, Martini A, Ruvoletto M, Quarta S, Fasolato S, Angeli P, Fassina G, Pontisso P. Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. Sci Rep 2019;9:20126. [PMID: 31882893 DOI: 10.1038/s41598-019-56633-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
252 Zhang S, Zhang K, Ji P, Zheng X, Jin J, Feng M, Liu P. GABPA predicts prognosis and inhibits metastasis of hepatocellular carcinoma. BMC Cancer 2017;17:380. [PMID: 28549418 DOI: 10.1186/s12885-017-3373-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
253 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. J Cancer. 2017;8:152-161. [PMID: 28243319 DOI: 10.7150/jca.16523] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
254 Pelizzaro F, Sammarco A, Dadduzio V, Pastorelli D, Giovanis P, Soldà C, Rizzato MD, Lombardi G, Lonardi S, Peserico G, Imondi A, Sartori A, Maddalo G, Farinati F. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Digestive and Liver Disease 2019;51:1713-9. [DOI: 10.1016/j.dld.2019.06.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
255 Uchikawa S, Kawaoka T, Namba M, Kodama K, Ohya K, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Chayama K, Aikata H. Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. Liver Cancer 2020;9:148-55. [PMID: 32399429 DOI: 10.1159/000503829] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
256 Li L, Knutsdottir H, Hui K, Weiss MJ, He J, Philosophe B, Cameron AM, Wolfgang CL, Pawlik TM, Ghiaur G, Ewald AJ, Mezey E, Bader JS, Selaru FM. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight 2019;4:121490. [PMID: 30674722 DOI: 10.1172/jci.insight.121490] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 16.0] [Reference Citation Analysis]
257 Du L, Wang M, Li H, Li N, Wang F, Mei J. Identification of CCL20 and LCN2 as Efficient Serological Tools for Detection of Hepatocellular Carcinoma. Disease Markers 2022;2022:1-7. [DOI: 10.1155/2022/7758735] [Reference Citation Analysis]
258 Di Poto C, He S, Varghese RS, Zhao Y, Ferrarini A, Su S, Karabala A, Redi M, Mamo H, Rangnekar AS, Fishbein TM, Kroemer AH, Tadesse MG, Roy R, Sherif ZA, Kumar D, Ressom HW. Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection. PLoS One 2018;13:e0192748. [PMID: 29538406 DOI: 10.1371/journal.pone.0192748] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
259 Vogl TJ, Gruber-Rouh T. HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer. Dig Dis Sci 2019;64:959-67. [PMID: 30835030 DOI: 10.1007/s10620-019-05542-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
260 Imai K, Takai K, Miwa T, Taguchi D, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1795. [PMID: 32635536 DOI: 10.3390/cancers12071795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
261 Cariani E, Missale G. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. Liver Int. 2019;39:1608-1621. [PMID: 31314948 DOI: 10.1111/liv.14192] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
262 Uchikawa S, Kawaoka T, Aikata H, Kodama K, Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res 2018;48:814-20. [PMID: 29682855 DOI: 10.1111/hepr.13180] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
263 Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018;69:278-285. [PMID: 29551708 DOI: 10.1016/j.jhep.2018.02.032] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 13.3] [Reference Citation Analysis]
264 Hsu WH, Sue SP, Liang HL, Tseng CW, Lin HC, Wen WL, Lee MY. Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan. Front Public Health 2021;9:711723. [PMID: 34604157 DOI: 10.3389/fpubh.2021.711723] [Reference Citation Analysis]
265 Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017;14:527-39. [PMID: 28676707 DOI: 10.1038/nrgastro.2017.72] [Cited by in Crossref: 176] [Cited by in F6Publishing: 168] [Article Influence: 35.2] [Reference Citation Analysis]
266 Navin PJ, Venkatesh SK. Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. J Clin Transl Hepatol 2019;7:72-85. [PMID: 30944823 DOI: 10.14218/JCTH.2018.00032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
267 Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Chayama K, Aikata H. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. Cancers (Basel) 2021;13:3958. [PMID: 34439111 DOI: 10.3390/cancers13163958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
268 Liu H, Chen H, Wu X, Sun Y, Wang Y, Zeng Y, Chen G, Liu X, Xing X, Zhao B, Liu J. The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection. Cancer Manag Res 2019;11:2935-46. [PMID: 31114342 DOI: 10.2147/CMAR.S190561] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
269 Heimbach JK. Evolution of Liver Transplant Selection Criteria and U.S. Allocation Policy for Patients with Hepatocellular Carcinoma. Semin Liver Dis 2020;40:358-64. [PMID: 32942324 DOI: 10.1055/s-0040-1709492] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
270 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
271 Bertot LC, Adams LA. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2019;13:179-87. [PMID: 30791782 DOI: 10.1080/17474124.2019.1549989] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
272 Schwamborn K, Kriegsmann M, Weichert W. MALDI imaging mass spectrometry - From bench to bedside. Biochim Biophys Acta Proteins Proteom 2017;1865:776-83. [PMID: 27810414 DOI: 10.1016/j.bbapap.2016.10.014] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
273 Liu S, Xu X, Fang Z, Ning Y, Deng B, Pan X, He Y, Yang Z, Huang K, Li J. Piezo1 impairs hepatocellular tumor growth via deregulation of the MAPK-mediated YAP signaling pathway. Cell Calcium 2021;95:102367. [PMID: 33610907 DOI: 10.1016/j.ceca.2021.102367] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
274 Rodriguez Villalvazo Y, McDanel JS, Beste LA, Sanchez AJ, Vaughan-Sarrazin M, Katz DA. Effect of travel distance and rurality of residence on initial surveillance for hepatocellular carcinoma in VA primary care patient with cirrhosis. Health Serv Res 2020;55:103-12. [PMID: 31763691 DOI: 10.1111/1475-6773.13241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
275 Montealegre JR, Singl AG, Asrani SK, El-Serag H; Montealegre et al. A Conceptual Model for Implementation and Evaluation of Interventions Across the Hepatocellular Carcinoma Care Continuum. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00755-2. [PMID: 34274512 DOI: 10.1016/j.cgh.2021.07.024] [Reference Citation Analysis]
276 Li SQ, Chen Q, Qin HX, Yu YQ, Weng J, Mo QR, Yin XF, Lin Y, Liao WJ. Long Intergenic Nonprotein Coding RNA 0152 Promotes Hepatocellular Carcinoma Progression by Regulating Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway through miR-139/PIK3CA. Am J Pathol 2020;190:1095-107. [PMID: 31954697 DOI: 10.1016/j.ajpath.2019.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
277 Cheng Q, Tong TJ, Li Z, Hu SH, Chen DB, Wang SQ, Zhu JY. Paradoxical effects of cellular senescence-inhibited gene involved in hepatocellular carcinoma migration and proliferation by ERK pathway and mesenchymal-like markers. Onco Targets Ther 2019;12:2035-46. [PMID: 30936720 DOI: 10.2147/OTT.S188449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
278 Ashktorab H, Kupfer SS, Brim H, Carethers JM. Racial Disparity in Gastrointestinal Cancer Risk. Gastroenterology. 2017;153:910-923. [PMID: 28807841 DOI: 10.1053/j.gastro.2017.08.018] [Cited by in Crossref: 99] [Cited by in F6Publishing: 98] [Article Influence: 19.8] [Reference Citation Analysis]
279 Ha J, Chaudhri A, Avirineni A, Pan JJ. Burden of hepatocellular carcinoma among hispanics in South Texas: a systematic review. Biomark Res 2017;5:15. [PMID: 28439416 DOI: 10.1186/s40364-017-0096-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
280 Tansel A, Katz LH, El-Serag HB, Thrift AP, Parepally M, Shakhatreh MH, Kanwal F. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1207-1217. e4. [PMID: 28215616 DOI: 10.1016/j.cgh.2017.02.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
281 Lim TR, Hazlehurst JM, Oprescu AI, Armstrong MJ, Abdullah SF, Davies NP, Flintham R, Balfe P, Mutimer DJ, McKeating JA, Tomlinson JW. Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. Clin Endocrinol (Oxf). 2019;90:440-448. [PMID: 30586166 DOI: 10.1111/cen.13924] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
282 Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol 2019;71:523-33. [PMID: 31145929 DOI: 10.1016/j.jhep.2019.05.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
283 Wu G, Zheng K, Xia S, Wang Y, Meng X, Qin X, Cheng Y. MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in Hepatocellular Carcinoma. J Exp Clin Cancer Res 2016;35:89. [PMID: 27259866 DOI: 10.1186/s13046-016-0368-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
284 Huang KT, Kuo IY, Tsai MC, Wu CH, Hsu LW, Chen LY, Kung CP, Cheng YF, Goto S, Chou YW, Chen CL, Lin CC, Chen KD. Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma. Mol Ther Nucleic Acids 2017;9:274-83. [PMID: 29246306 DOI: 10.1016/j.omtn.2017.10.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
285 Tang C, Ma J, Liu X, Liu Z. Identification of a prognostic signature of nine metabolism-related genes for hepatocellular carcinoma. PeerJ 2020;8:e9774. [PMID: 32953265 DOI: 10.7717/peerj.9774] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
286 Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology. 2017;152:745-761. [PMID: 28043904 DOI: 10.1053/j.gastro.2016.11.048] [Cited by in Crossref: 373] [Cited by in F6Publishing: 376] [Article Influence: 62.2] [Reference Citation Analysis]
287 Liu F, Luo L, Liu Z, Wu S, Zhang W, Li Q, Peng Y, Wei Y, Li B. A genetic variant in the promoter of CD46 is associated with the risk and prognosis of hepatocellular carcinoma. Mol Carcinog 2020;59:1243-55. [PMID: 32869896 DOI: 10.1002/mc.23252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
288 Brar TS, Hilgenfeldt E, Soldevila-pico C. Etiology and Pathogenesis of Hepatocellular Carcinoma. In: Liu C, editor. Precision Molecular Pathology of Liver Cancer. Cham: Springer International Publishing; 2018. pp. 1-15. [DOI: 10.1007/978-3-319-68082-8_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
289 Tang Y, Jiang M, Jiang HM, Ye ZJ, Huang YS, Li XS, Qin BY, Zhou RS, Pan HF, Zheng DY. The Roles of circRNAs in Liver Cancer Immunity. Front Oncol 2020;10:598464. [PMID: 33614486 DOI: 10.3389/fonc.2020.598464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
290 Hu J, Li P, Song Y, Ge YX, Meng XM, Huang C, Li J, Xu T. Progress and prospects of circular RNAs in Hepatocellular carcinoma: Novel insights into their function. J Cell Physiol. 2018;233:4408-4422. [PMID: 28833094 DOI: 10.1002/jcp.26154] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
291 Roudi R, D'Angelo A, Sirico M, Sobhani N. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. Int Immunopharmacol 2021;101:108322. [PMID: 34735916 DOI: 10.1016/j.intimp.2021.108322] [Reference Citation Analysis]
292 Bian Z, Hann HW, Ye Z, Yin C, Wang Y, Fang W, Wan S, Wang C, Tao K. Ferritin level prospectively predicts hepatocarcinogenesis in patients with chronic hepatitis B virus infection. Oncol Lett 2018;16:3499-508. [PMID: 30127954 DOI: 10.3892/ol.2018.9099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
293 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 982] [Article Influence: 156.8] [Reference Citation Analysis]
294 Li L, Shen L, Ma J, Zhou Q, Li M, Wu H, Wei M, Zhang D, Wang T, Qin S, Xing T. Evaluating Distribution and Prognostic Value of New Tumor-Infiltrating Lymphocytes in HCC Based on a scRNA-Seq Study With CIBERSORTx. Front Med (Lausanne) 2020;7:451. [PMID: 33043022 DOI: 10.3389/fmed.2020.00451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
295 Sun J, Li Y, Wang Y, Liu Y, Liu Y, Wang X. Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of Chronic hepatitis B patients with compensated cirrhosis: a retrospective cohort study. Infect Agent Cancer 2018;13:17. [PMID: 29796061 DOI: 10.1186/s13027-018-0189-2] [Reference Citation Analysis]
296 Shang W, Adzika GK, Li Y, Huang Q, Ding N, Chinembiri B, Rashid MS, Machuki JO. Molecular mechanisms of circular RNAs, transforming growth factor-β, and long noncoding RNAs in hepatocellular carcinoma. Cancer Med 2019;8:6684-99. [PMID: 31523930 DOI: 10.1002/cam4.2553] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
297 Munir J, Yoon JK, Ryu S. Therapeutic miRNA-Enriched Extracellular Vesicles: Current Approaches and Future Prospects. Cells 2020;9:E2271. [PMID: 33050562 DOI: 10.3390/cells9102271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
298 Liu K, Zhang Y, Zhang C, Zhang Q, Li J, Xiao F, Li Y, Zhang R, Dou D, Liang J, Qin J, Lin Z, Zhao D, Jiang M, Liang Z, Su J, Gupta VP, He M, Yang X. Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma. Oncotarget 2016;7:56798-810. [PMID: 27462864 DOI: 10.18632/oncotarget.10792] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
299 Llovet JM, Zucman-rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2. [DOI: 10.1038/nrdp.2016.18] [78495111110.1038/nrdp.2016.18','', '1948-5182')">Reference Citation Analysis]
300 Liu L, Qi X, Gui Y, Huo H, Yang X, Yang L. Overexpression of circ_0021093 circular RNA forecasts an unfavorable prognosis and facilitates cell progression by targeting the miR-766-3p/MTA3 pathway in hepatocellular carcinoma. Gene 2019;714:143992. [PMID: 31330234 DOI: 10.1016/j.gene.2019.143992] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
301 Kuftinec GN, Levy R, Kieffer DA, Medici V. Hepatocellular Carcinoma and Associated Clinical Features in Latino and Caucasian Patients from a Single Center. Ann Hepatol 2019;18:177-86. [PMID: 31113588 DOI: 10.5604/01.3001.0012.7910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
302 Wang F, Li L, Piontek K, Sakaguchi M, Selaru FM. Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology 2018;67:940-54. [PMID: 29023935 DOI: 10.1002/hep.29586] [Cited by in Crossref: 126] [Cited by in F6Publishing: 118] [Article Influence: 31.5] [Reference Citation Analysis]
303 Hsu Y, Ho H, Lee T, Huang Y, Wu M, Lin J, Wu C, El‐serag HB. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir. J Viral Hepat 2018;25:543-51. [DOI: 10.1111/jvh.12832] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
304 Akhdar H, El Shamieh S, Musso O, Désert R, Joumaa W, Guyader D, Aninat C, Corlu A, Morel F. The rs3957357C>T SNP in GSTA1 Is Associated with a Higher Risk of Occurrence of Hepatocellular Carcinoma in European Individuals. PLoS One 2016;11:e0167543. [PMID: 27936036 DOI: 10.1371/journal.pone.0167543] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
305 Zhao G, Zhang A, Sun S, Ding Y. Long non-coding RNA LINC00173 enhances cisplatin resistance in hepatocellular carcinoma via the microRNA-641/RAB14 axis. Oncol Lett 2021;21:371. [PMID: 33777195 DOI: 10.3892/ol.2021.12632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]